Therapeutic Advances in Psychopharmacology

Papers
(The median citation count of Therapeutic Advances in Psychopharmacology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The role of Facebook groups in the management and raising of awareness of antidepressant withdrawal: is social media filling the void left by health services?45
What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications39
Clozapine discontinuation withdrawal symptoms in schizophrenia29
Current antipsychotic agent use and risk of venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis of observational studies29
Repetitive transcranial magnetic stimulation for major depressive disorder: basic principles and future directions28
Transcranial magnetic stimulation for post-traumatic stress disorder25
Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review24
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review24
Clinical pharmacist interventions in elderly patients with mental disorders in primary care focused on psychotropics: a retrospective pre–post observational study24
History repeating: guidelines to address common problems in psychedelic science24
Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders22
The role of lumateperone in the treatment of schizophrenia21
Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review20
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action20
Cognitive effects of vortioxetine in older adults: a systematic review19
Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review18
Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study18
Efficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review18
Asenapine: an atypical antipsychotic with atypical formulations17
Trends in benzodiazepine receptor agonists use and associated factors in the Belgian general older population: analysis of the Belgian health interview survey data17
Advances in pharmacotherapy for postpartum depression: a structured review of standard-of-care antidepressants and novel neuroactive steroid antidepressants16
Synthetic opioids: a review and clinical update15
Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update15
Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate14
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series14
Pathophysiology, prognosis and treatment of tardive dyskinesia14
Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey12
Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA12
Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine12
Liquorice for pain?11
Exercise interventions to reduce anxiety in mid-life and late-life anxiety disorders and subthreshold anxiety disorder: a systematic review11
Classic psychedelics, health behavior, and physical health11
The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics11
Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry10
Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies10
Excess deaths in treatment-resistant depression9
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia9
Identification of clinical phenotypes in schizophrenia: the role of lurasidone9
Treatment strategies for clozapine-induced hypotension: a systematic review9
Clozapine re-challenge and initiation following neutropenia: a review and case series of 14 patients in a high-secure forensic hospital9
Service-user efforts to maintain their wellbeing during and after successful withdrawal from antipsychotic medication8
Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study8
Will psilocybin lose its magic in the clinical setting?8
The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson’s disease: meta-analysis of randomized controlled trials8
CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine8
MTORC1 signaling as a biomarker in major depressive disorder and its pharmacological modulation by novel rapid-acting antidepressants8
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence8
Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study8
Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study7
Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations7
Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report7
Enduring neurological sequelae of benzodiazepine use: an Internet survey7
Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?6
Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis6
Prescription attitudes and practices regarding clozapine among Serbian psychiatrists: results of a nationwide survey6
Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study6
Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial6
Managing medical and psychiatric multimorbidity in older patients6
Estimation of cardiac QTc intervals in people prescribed antipsychotics: a comparison of correction factors5
Outcomes of hyperbolic tapering of antidepressants5
Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital5
Using a fingerstick test for haematological monitoring in patients treated with clozapine5
Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report5
Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation5
Hamlet’s augury: how to manage discontinuation of mood stabilizers in bipolar disorder5
Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan5
Association of plasma VEGF levels and the antidepressant effects of ketamine in patients with depression5
Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review4
Incidence of hyperthyroidism in patients with bipolar or schizoaffective disorder with or without lithium: 21-year follow-up from the LiSIE retrospective cohort study4
Clozapine for treatment resistance in early psychosis: a survey of UK clinicians’ training, knowledge and confidence4
Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review4
Brexanolone: panacea for postpartum depression? Reply to: ‘Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?’4
The effect of non-adherence to antipsychotic treatment on rehospitalization in patients with psychotic disorders4
Reasons for admission to a general medical hospital for patients taking clozapine3
Olanzapine for the treatment of ICU delirium: a systematic review and meta-analysis3
Duration of prior psychotic illness and clozapine response: a retrospective observational study using electronic health records3
The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial3
Clinical outcomes following switching antipsychotic treatment due to market withdrawal: a retrospective naturalistic cohort study of pipotiazine palmitate injection (Piportil Depot) discontinuation, s3
Optimizing treatment for older adults with depression3
Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia versus healthy controls: a prospective ‘true-to-life’ study3
Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan3
Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation3
Agomelatine for postpartum depression and breastfeeding3
The place of long-acting injectable antipsychotics in the treatment of schizophrenia3
Ketamine for bipolar depression: an updated systematic review3
Vortioxetine as adjunctive therapy in the treatment of schizophrenia3
Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications3
Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study3
0.024812936782837